The Cocktail Report (sound really smart around your friends):
UCLA scientists published in Nature Aging (April 16, 2026) the first definitive identification of a specific population of senescent macrophages (immune cells that have stopped functioning normally but refuse to die, sometimes called "zombie cells") that drive chronic liver inflammation and fatty liver disease.
The cells are identified by two molecular markers: p21 and TREM2, giving them the scientific name p21+TREM2+ macrophages.
In young, healthy livers, these zombie cells make up roughly 5% of liver macrophages. In aged livers, they balloon to 60 to 80% of the macrophage population.
The senolytic drug ABT-263 (navitoclax) selectively cleared these cells in mice with fatty liver disease, reducing liver weight from 7% to a healthy 4 to 5% of body weight, and cutting total body weight by 25%, all without any change in diet.
The same p21+TREM2+ signature was found elevated in human cirrhotic liver biopsies, suggesting the mechanism translates to people.
The study was led by Anthony Covarrubias, PhD, and graduate student Ivan Salladay-Perez at UCLA's David Geffen School of Medicine, funded in part by the NIH and Glenn Foundation for Medical Research.
MASLD (metabolic dysfunction-associated steatotic liver disease, the condition formerly known as NAFLD or non-alcoholic fatty liver disease) affects an estimated 30 to 40% of adults in the United States.
ABT-263 itself is too toxic for widespread human use due to side effects on platelets; the next step is screening for safer compounds that target the same cells.
A human trial of a derivative compound is considered plausible within 3 to 5 years; an approved therapy is likely 7 to 10+ years away.
The authors believe the same zombie macrophage mechanism may contribute to atherosclerosis, Alzheimer's disease, and cancer.
If you have ever been told your liver enzymes are elevated, been warned about fatty liver, or simply eat the modern American diet, this finding is directly relevant to your biology.
UCLA researchers have identified a precise cellular culprit behind fatty liver disease: a population of dysfunctional immune cells called p21+TREM2+ macrophages (senescent macrophages, immune cells that have gone dormant and stopped working but won't die, chronically leaking inflammatory signals into surrounding tissue).
In young, healthy livers, these cells represent about 5% of the liver's immune cell population. In aging livers, they swell to 60 to 80%.
The team, led by Anthony Covarrubias, PhD, at UCLA's David Geffen School of Medicine and published in Nature Aging on April 16, 2026, went further than identification: they cleared the cells using a senolytic drug called ABT-263 (navitoclax, a compound that forces stubborn senescent cells to finally die). Mice with fatty liver disease that received the treatment saw their liver weight drop from about 7% to a healthy 4 to 5% of body weight, and total body weight fell by roughly 25%, without any dietary change.
The same molecular signature was found elevated in human cirrhotic liver biopsies compared to healthy controls, a critical translational finding suggesting this is not just a mouse phenomenon.
MASLD (metabolic dysfunction-associated steatotic liver disease, the umbrella term now used for what was previously called non-alcoholic fatty liver disease or NAFLD) affects an estimated 30 to 40% of American adults, with no widely accessible cure. Right now the only FDA-approved medications are resmetirom (Rezdiffra, approved March 2024) and semaglutide, which received accelerated MASH approval in August 2025.
The honest caveat: ABT-263 is too toxic for broad clinical use because it also destroys platelets, so the researchers are now screening for safer compounds that target the same p21+TREM2+ signature. A human trial of a derivative drug is considered plausible within 3 to 5 years.
What makes this finding bigger than just liver disease is the authors' own framing: they believe the same zombie macrophage accumulation pattern may drive atherosclerosis, Alzheimer's disease, and cancer. One cellular mechanism, one potential class of drugs, multiple age-related diseases.
Why Should You Care?
Fatty liver disease is largely silent until it isn't. Most people who have it don't know it, and by the time symptoms appear, the liver may already be scarring.
A drug that clears the specific cells driving that process without requiring diet change would be a genuine breakthrough in how we treat the diseases of aging. The science is real, the human tissue data is encouraging, and the research team is now building toward a clinical candidate.
Citations:
Salladay-Perez I, Covarrubias AJ, et al. "p21+TREM2+ senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease." Nature Aging. April 16, 2026. DOI: 10.1038/s43587-026-01101-6. https://www.nature.com/articles/s43587-026-01101-6
UCLA Health Newsroom. "UCLA scientists identify zombie immune cells as a driver of fatty liver disease, inflammation and aging." April 16, 2026. https://newsroom.ucla.edu
SciTechDaily. "Scientists Find Way to Reverse Fatty Liver Disease Without Changing Diet." April 20, 2026. https://scitechdaily.com
